CD73 is associated with poor prognosis in high-grade serous ovarian cancer - PubMed (original) (raw)

. 2015 Nov 1;75(21):4494-503.

doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

Kathleen Spring 2, Sandra Pommey 2, Guillaume Chouinard 2, Isabelle Cousineau 2, Joshy George 3, Gregory M Chen 4, Deena M A Gendoo 4, Benjamin Haibe-Kains 4, Thomas Karn 5, Kurosh Rahimi 6, Cécile Le Page 2, Diane Provencher 7, Anne-Marie Mes-Masson 7, John Stagg 8

Affiliations

• PMID: 26363007
• DOI: 10.1158/0008-5472.CAN-14-3569

CD73 is associated with poor prognosis in high-grade serous ovarian cancer

Martin Turcotte et al. Cancer Res. 2015.

Abstract

The cell surface nucleotidase CD73 is an immunosuppressive enzyme involved in tumor progression and metastasis. Although preclinical studies suggest that CD73 can be targeted for cancer treatment, the clinical impact of CD73 in ovarian cancer remains unclear. In this study, we investigated the prognostic value of CD73 in high-grade serous (HGS) ovarian cancer using gene and protein expression analyses. Our results demonstrate that high levels of CD73 are significantly associated with shorter disease-free survival and overall survival in patients with HGS ovarian cancer. Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis associated with intraepithelial CD8(+) cells. Notably, CD73 gene expression was highest in the C1/stromal molecular subtype of HGS ovarian cancer and positively correlated with an epithelial-to-mesenchymal transition gene signature. Moreover, in vitro studies revealed that CD73 and extracellular adenosine enhance ovarian tumor cell growth as well as expression of antiapoptotic BCL-2 family members. Finally, in vivo coinjection of ID8 mouse ovarian tumor cells with mouse embryonic fibroblasts showed that CD73 expression in fibroblasts promotes tumor immune escape and thereby tumor growth. In conclusion, our study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in HGS ovarian cancers.

©2015 American Association for Cancer Research.

PubMed Disclaimer

Similar articles

• High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
  Bareche Y, Pommey S, Carneiro M, Buisseret L, Cousineau I, Thebault P, Chrobak P, Communal L, Allard D, Robson SC, Mes-Masson AM, Provencher D, Lapointe R, Stagg J. Bareche Y, et al. J Immunother Cancer. 2021 Mar;9(3):e001965. doi: 10.1136/jitc-2020-001965. J Immunother Cancer. 2021. PMID: 33771891 Free PMC article.
• Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma.
  Miyazaki M, Aoki M, Okado Y, Koga K, Hamasaki M, Nakagawa T, Sakata T, Nabeshima K. Miyazaki M, et al. Cancer Sci. 2020 Aug;111(8):3045-3056. doi: 10.1111/cas.14508. Epub 2020 Jun 22. Cancer Sci. 2020. PMID: 32473077 Free PMC article.
• CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
  Ma XL, Shen MN, Hu B, Wang BL, Yang WJ, Lv LH, Wang H, Zhou Y, Jin AL, Sun YF, Zhang CY, Qiu SJ, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Ma XL, et al. J Hematol Oncol. 2019 Apr 11;12(1):37. doi: 10.1186/s13045-019-0724-7. J Hematol Oncol. 2019. PMID: 30971294 Free PMC article.
• The roles of CD73 in cancer.
  Gao ZW, Dong K, Zhang HZ. Gao ZW, et al. Biomed Res Int. 2014;2014:460654. doi: 10.1155/2014/460654. Epub 2014 Jul 14. Biomed Res Int. 2014. PMID: 25126561 Free PMC article. Review.
• Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
  Yang J, Liao X, Yu J, Zhou P. Yang J, et al. Curr Med Chem. 2018;25(19):2260-2271. doi: 10.2174/0929867325666180117101114. Curr Med Chem. 2018. PMID: 29345574 Review.

Cited by

• Blockade of CD73 potentiates radiotherapy antitumor immunity and abscopal effects via STING pathway.
  An R, Wu C, Tang C, Zhang C, Han F, Xu Z, Zou Y, Wang J, Yuan Z, Jiang S, Liu L, Huang C, Tao Z. An R, et al. Cell Death Discov. 2024 Sep 16;10(1):404. doi: 10.1038/s41420-024-02171-4. Cell Death Discov. 2024. PMID: 39285178 Free PMC article.
• Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers.
  Myong S, Nguyen AQ, Challa S. Myong S, et al. Cancers (Basel). 2024 Sep 5;16(17):3085. doi: 10.3390/cancers16173085. Cancers (Basel). 2024. PMID: 39272943 Free PMC article. Review.
• Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.
  Wang F, Yang M, Luo W, Zhou Q. Wang F, et al. J Natl Cancer Cent. 2022 Oct 20;2(4):243-262. doi: 10.1016/j.jncc.2022.10.002. eCollection 2022 Dec. J Natl Cancer Cent. 2022. PMID: 39036549 Free PMC article. Review.
• PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
  Barlesi F, Cho BC, Goldberg SB, Yoh K, Zimmer Gelatti AC, Mann H, Gopinathan A, Bielecka ZF, Newton M, Aggarwal C. Barlesi F, et al. Future Oncol. 2024;20(29):2137-2147. doi: 10.1080/14796694.2024.2354160. Epub 2024 Jul 18. Future Oncol. 2024. PMID: 39023287 Free PMC article.
• The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.
  Wang L, Zhang J, Zhang W, Zheng M, Guo H, Pan X, Li W, Yang B, Ding L. Wang L, et al. Acta Pharm Sin B. 2024 May;14(5):1951-1964. doi: 10.1016/j.apsb.2023.12.004. Epub 2023 Dec 16. Acta Pharm Sin B. 2024. PMID: 38799637 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal